ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "prognostic factors and systemic lupus erythematosus (SLE)"

  • Abstract Number: 784 • 2018 ACR/ARHP Annual Meeting

    Prediction of Hospital-Acquired Bacterial Infections in Patients with SLE

    Pablo Castaño-Gonzalez1, Mauricio Restrepo-Escobar1,2, Laura Morales-Maya1, Tomás Urrego1, Simon Sandoval-Alvares1, Carlos Horacio Muñoz1,3, Adriana L Vanegas1,3, Daniel Jaramillo1,4, Gloria Vasquez1 and Luis Gonzalez-Naranjo1, 1Division of Rheumatology, Department of Internal Medicine, School of Medicine, Universidad de Antioquia, Medellin, Colombia, 2Hospital Universitario Pablo Tobon Uribe, Medellin, Colombia, 3Hospital Universitario de San Vicente Fundación, Medellín, Colombia, 4Hospital Universitario de San Vicente Fundación, Medellin, Colombia

    Background/Purpose: Patients with SLE have an increased risk of serious infections, including nosocomial infections, which are associated with potentially modifiable adverse outcomes. Our objective is…
  • Abstract Number: 671 • 2017 ACR/ARHP Annual Meeting

    A New Histological Index for Predicting a Decline in Kidney Function in Patients with Lupus Nephritis. a Mexican Cohort Study of 186 Patients with a Kidney Biopsy

    Marco Ulises Martinez-Martinez1, Cesar Eduardo Vallín Orozco2, David Martínez-Galla3 and Carlos Abud-Mendoza4, 1Unidad de Investigaciones Reumatológicas, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, 2Rheumatology, Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, 3Pathology, Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, 4Unidad de Investigaciones Reumatológicas y Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico

    -       Background/Purpose: The NIH indexes (of activity and chronicity) were proposed by Austin et al., in 1984. At the moment, there are therapies which can…
  • Abstract Number: 702 • 2017 ACR/ARHP Annual Meeting

    Positive Direct Coombs’ Test in the Absence of Hemolytic Anemia Predicts High Disease Activity and Poor Renal Response in Systemic Lupus Erythematosus

    Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan

    Background/Purpose: Direct Coombs' test in the absence of hemolytic anemia was newly included in the immunologic criterion of the SLICC/ACR 2012 criteria for SLE. Since…
  • Abstract Number: 2816 • 2017 ACR/ARHP Annual Meeting

    Prediction of Connective Tissue Disease in an at-Risk Cohort Using a Novel Interferon Stimulated Gene Expression Score

    Md Yuzaiful Md Yusof1,2, Yasser M El-Sherbiny1,3, Antonios Psarras1, Elizabeth M.A. Hensor1,4, Adewonuola Alase1, Alaa Mohamed1, Miriam Wittmann1,4, Paul Emery1,4 and Edward M Vital1,4, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 3Clinical Pathology dept., School of Medicine, Mansoura University, Mansoura, Egypt, 4NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Prediction of connective tissue disease in an at-risk cohort using a novel interferon stimulated gene expression scoreBackground/Purpose: A period of ANA positivity and other immune…
  • Abstract Number: 782 • 2016 ACR/ARHP Annual Meeting

    Can We Identify Who Benefits from Mycophenolate Mofetil in Systemic Lupus Erythematosus? a Systematic Review

    Claudia Mendoza Pinto1,2, Carmelo Pirone3, Ben Parker4 and Ian N. Bruce5, 1Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR, IMSS, Puebla, Mexico, 2Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 3Rheumatology Unit, Sapienza University of Rome, Department of Internal Medicine and Medical Specialties,, Rome, Italy, 4Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, 5Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom

    Background/Purpose: Mycophenolate mofetil (MMF) is widely used in the treatment of SLE however little is known about factors that may predict response or other outcomes…
  • Abstract Number: 1818 • 2016 ACR/ARHP Annual Meeting

    Predictors for Mortality in Hospitalized Patients with Systemic Lupus Erythematosus from 1999 to 2009: A Follow-up Multicenter Study in China

    Xuebing Feng1, Wenyou Pan2, Lin Liu3, Min Wu4, Lingyun Sun5 and Jiangsu Lupus Collaborative Group, 1Department of Rheumatology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, 2Huaian First People’s Hospital, Huaian, China, 3Xuzhou No. 4 People’s Hospital, Xuzhou, China, 4the 3rd Affiliated Hospital of Suzhou University, Changzhou, China, 5the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China

    Background/Purpose: To find out prognostic factors predicting the outcome of Chinese patients with systemic lupus erythematosus (SLE) at the time of their first admission. Methods: A…
  • Abstract Number: 2824 • 2016 ACR/ARHP Annual Meeting

    Lack of Partial Renal Response By 12 Weeks after Induction Therapy Is an Indicator to Switch the Treatment in Lupus Nephritis Class III or IV for Reducing Future Damage Accrual

    Hironari Hanaoka1, Hidehiro Yamada2, Tomofumi Kiyokawa3, Harunobu Iida1, Takeshi Suzuki1, Yoshioki Yamasaki4, Seido Ooka5, Hiroko Nagafuchi3, Takahiro Okazaki3, Daisuke Ichikawa6, Sayuri Shirai6, Yugo Shibagaki7, Junki Koike8 and Shoichi Ozaki3, 1Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 2Rheumatology, Seirei Yokohama Hospital, Yokohama, Japan, 3Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 4Internal Medicie, St. Marianna University School of Medicine, Kawasaki, Japan, 5Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 6Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 7Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, K, Japan, 8Department of Pathology, St. Marianna University School of Medicine, Kawasaki, Japan

    Background/Purpose: Lupus nephritis (LN) class III or IV is associated with a poor prognosis for both patient and renal survival. The guideline or recommendation for…
  • Abstract Number: 2828 • 2016 ACR/ARHP Annual Meeting

    Difference of d-Dimer Between Two Time Points Predicts Prognosis of Admitted Patients with SLE Flare up

    Sejin Byun1, Seung Min Jung1, Sang-Won Lee2, Yong-Beom Park2 and Jason Jungsik Song2, 1Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, The Republic of, 2Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

    Background/Purpose: Even though the survival rate among SLE patients has improved over the past few decades, the mortality rate caused by the acute flare of…
  • Abstract Number: 951 • 2012 ACR/ARHP Annual Meeting

    A Systematic Review of Quality of Prognosis Studies in Systemic Lupus Erythematosus

    Lily Siok Hoon Lim1, Senq-J Lee2, Brian M. Feldman3, D. D. Gladman4, Eleanor Pullenayegum5 and Earl D. Silverman6, 1Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, 2Division of Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, 3Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 4Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 5Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada, 6Rheumatology, Pediatric Rheumatology Collaborative Study Group (PRSCG), Toronto, ON, Canada

    Background/Purpose: Prognosis studies study future outcomes and/or seek to identify predictive or associative factors associated with outcomes. Strong and consistent prognostic factors can be used…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology